BRAF and colorectal cancer: Preclinical and clinical studies showed that the lack of efficacy of single-agent BRAF (encorafenib) or dual BRAF and MEK inhibition (encorafenib plus binimetinib) in BRAF V600E-mutated colorectal cancer is related to rapid EGFR-mediated adaptive feedback.